Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell

In Vivo Imaging of Human Malignant Mesothelioma Grown Orthotopically in the Peritoneal Cavity of Nude Mice

(2012) Mingqian Feng et al.   Journal of Cancer

Targeting IGF-1R: throwing out the baby with the bathwater?

(2011) B Basu et al.   BRITISH JOURNAL OF CANCER

Surgical Treatment of Malignant Pleural Mesothelioma

(2011) Andrew J. Kaufman et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

(2010) A Gualberto et al.   BRITISH JOURNAL OF CANCER

Biological Rationale and Current Clinical Experience With Anti-Insulin-Like Growth Factor 1 Receptor Monoclonal Antibodies in Treating Sarcoma

(2010) David Olmos et al.   CANCER JOURNAL

Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy

(2010) J. Zha et al.   CLINICAL CANCER RESEARCH

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer

(2010) Diane Lauren Reidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines

(2009) Kiyonori Kai et al.   CANCER LETTERS

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

(2009) A Gualberto et al.   ONCOGENE

High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)

(2009) Yixuan Gong et al.   PLoS One

Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody

(2008) L. Cao et al.   CANCER RESEARCH

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials

(2008) J. Rodon et al.   MOLECULAR CANCER THERAPEUTICS